Literature DB >> 3955304

Identification of 6-oxo-prostaglandin E1 as a naturally occurring prostanoid generated by rat lung.

C N Berry, R J Griffiths, J R Hoult, P K Moore, G W Taylor.   

Abstract

The spontaneous release of prostanoids from rat isolated perfused lungs was studied after acid/organic extraction of perfusates by bioassay, radioimmunoassay, thin layer and high performance liquid chromatographic methods and by gas chromatography-negative ion mass spectroscopy (g.c.n.i.m.s.). An acid/organic extractable anti-aggregatory vasodilator prostaglandin which inhibited the twitch response of the field-stimulated guinea-pig vas deferens was released from the Krebs-perfused rat lung in nanogram amounts similar to those of other detected prostanoids. Parallel biological assay suggested that this prostaglandin had very closely similar pharmacological activity to authentic 6-oxo-prostaglandin E1 (6-oxo-PGE1), a metabolite of prostacyclin (PGI2) generated by the action of the enzyme 9-hydroxyprostaglandin dehydrogenase (9-PGDH). 6-oxo-PGE1 was identified conclusively in extracts of rat lung perfusate by thin layer chromatography, high performance liquid chromatography and g.c./m.s. combined with bioassay (inhibition of platelet aggregation), and its covalent structure was defined by g.c. negative ion chemical ionization mass spectroscopy. The rank order of spontaneous release of prostanoids (measured by radioimmunoassay) from the perfused rat lung was 6-oxo-PGF1 alpha greater than thromboxane B2 (TXB2) greater than PGE2 greater than 6-oxo-PGE1 (measured biologically) greater than PGF2 alpha. Release of all five prostanoids was inhibited by indomethacin, but only that of 6-oxo-PGE1 was inhibited by naringenin. Rat lung 100,000 g cytosolic supernatants contained 9-PGDH activity capable of removing 9 beta-tritium from labelled prostacyclin and forming an acid/organic extractable 6-oxo-PGE1-like anti-aggregatory substance. This 9-PGDH activity was inhibited by naringenin (IC50 10.3 microM). 6 The relevance of these findings to the possible physiological role of 6-oxo-PGE1 in the lung is discussed, and we propose that 6-oxo-PGE, should be accorded the status ofa physiologically relevant, naturally occurring metabolite of arachidonic acid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3955304      PMCID: PMC1916551          DOI: 10.1111/j.1476-5381.1986.tb10821.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  The development of antisera to prostaglandins B2 and F2alpha and their analysis using solid-phase and double antibody radioimmunoassay methods.

Authors:  K K Dighe; H A Emslie; L K Henderson; L Simon
Journal:  Br J Pharmacol       Date:  1975-12       Impact factor: 8.739

2.  Cardiovascular responses to 6-keto-prostaglandin E1 in the dogs.

Authors:  J Van Dam; T M Fitzpatrick; L S Friedman; P W Ramwell; J C Rose; P A Kot
Journal:  Proc Soc Exp Biol Med       Date:  1981-01

3.  Effects of 6-keto-prostaglandin E1 on perinatal pulmonary vascular resistance.

Authors:  M L Tod; S Cassin
Journal:  Proc Soc Exp Biol Med       Date:  1981-01

4.  6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.

Authors:  O V Miller; J W Aiken; R J Shebuski; R R Gorman
Journal:  Prostaglandins       Date:  1980-08

5.  6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue.

Authors:  E K Jackson; W A Herzer; J B Zimmerman; R A Branch; J A Oates; J F Gerkens
Journal:  J Pharmacol Exp Ther       Date:  1981-01       Impact factor: 4.030

6.  Hypotensive and renovascular actions of 6-keto-prostaglandin E1, a metabolite of prostacyclin.

Authors:  C P Quilley; P Y Wong; J C McGiff
Journal:  Eur J Pharmacol       Date:  1979-08-01       Impact factor: 4.432

7.  Age-dependent changes in the synthesis and catabolism of 6 oxo PGE1 and other prostanoids by the rat kidney in vitro.

Authors:  R J Griffiths; C N Berry; J R Hoult; P K Moore
Journal:  Biochem Pharmacol       Date:  1985-01-15       Impact factor: 5.858

8.  6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.

Authors:  C P Quilley; J C McGiff; W H Lee; F F Sun; P Y Wong
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

9.  Hepatic metabolism of prostacyclin (PGI2) in the rabbit: formation of a potent novel inhibitor of platelet aggregation.

Authors:  P Y Wong; K U Malik; D M Desiderio; J C McGiff; F F Sun
Journal:  Biochem Biophys Res Commun       Date:  1980-03-28       Impact factor: 3.575

10.  Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.

Authors:  P Y Wong; W H Lee; P H Chao; R F Reiss; J C McGiff
Journal:  J Biol Chem       Date:  1980-10-10       Impact factor: 5.157

View more
  4 in total

1.  Endothelium-derived relaxing factor and the effects of acetylcholine and histamine on resistance blood vessels.

Authors:  R Bhardwaj; P K Moore
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

2.  Eicosanoid synthesis in duodenal ulcer disease: decrease in leukotriene C4 by colloidal bismuth subcitrate.

Authors:  A Ahmed; P R Salmon; C R Cairns; M Hobsley; J R Hoult
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

3.  Kinin-induced prostaglandin release in rat colon does not display serosal/mucosal 'sidedness' after epithelial removal.

Authors:  J R Hoult; J A Phillips
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

4.  Secretory effects of kinins on colonic epithelium in relation to prostaglandins released from cells of the lamina propria.

Authors:  J A Phillips; J R Hoult
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.